Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseases

Source: Trefoil Therapeutics

AGC Biologics, a global Contract Development and Manufacturing Organization for Biopharmaceuticals, and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound, TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore lost vision in patients with corneal diseases by regenerating corneal tissue. 

Trefoil Therapeutics selected AGC Biologics for their deep technical expertise and proven abilities in cGMP manufacture of protein-based therapeutics from preclinical to commercial production, after a 3-month selection process. David Eveleth, PhD, CEO, Trefoil Therapeutics, commented, “AGC Biologics’ extensive experience in cGMP manufacturing makes them an ideal company to help us move TTHX1114 forward. We believe our engineered FGF-1, which is expected to enter clinical trials during 2020 in an intracameral formulation for the treatment of corneal endothelial dystrophies, has the potential to make a substantial difference in patients’ lives.”

Patricio Massera, CEO, AGC Biologics states, “AGC Biologics is delighted to assist Trefoil Therapeutics with the production of this life changing product. Our teams will work together in an open and collaborative manner, and we are excited about the project’s potential.”

AGC Biologic’s global manufacturing footprint includes a cGMP-compliant facility in Heidelberg, Germany, which will begin manufacturing TTHX1114 in the coming months.

Related Content